{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:18:12Z","timestamp":1783160292653,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.IUMS.REC.1402.382"],"award-info":[{"award-number":["IR.IUMS.REC.1402.382"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["4040233"],"award-info":[{"award-number":["4040233"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.109990","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T06:47:00Z","timestamp":1779518820000},"page":"109990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents"],"prefix":"10.1016","volume":"179","author":[{"given":"Zahra","family":"Zakeri Khatir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motahareh","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Tavakkoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Irannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Foroumadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omidreza","family":"Firuzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.109990_bb0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.mayocpiqo.2021.05.005","article-title":"Cancer mortality rates increasing vs cardiovascular disease mortality decreasing in the world: future implications","volume":"5","author":"ReFaey","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hsc.13156","article-title":"Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries","volume":"30","author":"\u015eahin","year":"2022","journal-title":"Health Soc. Care Community"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109990_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41571-024-00945-4","article-title":"Two decades of advances in clinical oncology\u2014lessons learned and future directions","volume":"21","author":"Banerjee","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bioorg.2026.109990_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114314","article-title":"Recent advances of antitumor shikonin\/alkannin derivatives: a comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action","volume":"235","author":"Valipour","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109990_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70071","article-title":"Anticancer and anti-inflammatory potential of coptisine as a planar quaternary benzo [C] phenanthridine alkaloid with G-quadruplex DNA telomeric induction activity","volume":"86","author":"Valipour","year":"2025","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.109990_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108117","article-title":"Design, synthesis, and structure\u2013activity relationships of five-membered heterocyclic incorporated aryl (alkyl) azoles: from antiproliferative thiazoles to safer anticonvulsant oxadiazoles","volume":"155","author":"Valipour","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109990_bb0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/ph16020299","article-title":"Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective","volume":"16","author":"Kumar","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"18","key":"10.1016\/j.bioorg.2026.109990_bb0055","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.2174\/0115701808344031241126104914","article-title":"Advances in isatin-derived compounds for modern cancer therapy: a comprehensive review","volume":"21","author":"Gupta","year":"2024","journal-title":"Lett. Drug Des. Discovery"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109990_bb0060","doi-asserted-by":"crossref","first-page":"1900367","DOI":"10.1002\/ardp.201900367","article-title":"Recent advances in isatin hybrids as potential anticancer agents","volume":"353","author":"Ding","year":"2020","journal-title":"Arch. Pharm."},{"issue":"39","key":"10.1016\/j.bioorg.2026.109990_bb0065","doi-asserted-by":"crossref","first-page":"32188","DOI":"10.1039\/D5RA05002B","article-title":"A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020-2025)","volume":"15","author":"Alshams","year":"2025","journal-title":"RSC Adv."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109990_bb0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1248\/cpb.c15-00153","article-title":"Synthetic approaches for sulfur derivatives containing 1,2,4-triazine moiety: their activity for in vitro screening towards two human cancer cell lines","volume":"63","author":"Karczmarzyk","year":"2015","journal-title":"Chem. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0075","first-page":"1","article-title":"Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors","volume":"13","author":"Ranjbar","year":"2018","journal-title":"Res. Pharm. Sci."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109990_bb0080","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.bmc.2014.10.002","article-title":"In vitro antitumor activity evaluation of some 1,2,4-triazine derivatives bearing piperazine amide moiety against breast cancer cells","volume":"22","author":"Yurtta\u015f","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109990_bb0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/17460441.2023.2241366","article-title":"Drug design strategies that aim to improve the low solubility and poor bioavailability conundrum in quercetin derivatives","volume":"18","author":"Alizadeh","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109990_bb0090","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109990_bb0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/03602532.2021.1970178","article-title":"Drug metabolic stability in early drug discovery to develop potential lead compounds","volume":"53","author":"Gajula","year":"2021","journal-title":"Drug Metab. Rev."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109990_bb0100","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109990_bb0105","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.3390\/ijms26136147","article-title":"Phosphorus-derived isatin hydrazones: synthesis, structure, thromboelastography, antiplatelet, and anticoagulation activity evaluation","volume":"26","author":"Samorodov","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109990_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cryst13020305","article-title":"Synthesis and characterizations of novel isatin-s-triazine hydrazone derivatives; X-ray structure, Hirshfeld analysis and DFT calculations","volume":"13","author":"Al-Rasheed","year":"2023","journal-title":"Crystals"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109990_bb0115","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.apsb.2023.01.014","article-title":"Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109990_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11912-022-01199-y","article-title":"Targeting apoptosis in cancer","volume":"24","author":"Singh","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109990_bb0125","article-title":"A systematic review of apoptosis in correlation with cancer: should apoptosis be the ultimate target for cancer treatment?","volume":"14","author":"Abaza","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.bioorg.2026.109990_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2058-y","article-title":"Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13578-022-00887-3","article-title":"Three-dimensional in vitro culture models in oncology research","volume":"12","author":"Jubelin","year":"2022","journal-title":"Cell Biosci."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109990_bb0140","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.7150\/ijbs.96469","article-title":"Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research","volume":"20","author":"Esposito","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109990_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050638","article-title":"Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells","volume":"11","author":"Firuzi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109990_bb0150","doi-asserted-by":"crossref","first-page":"1498141","DOI":"10.3389\/fbioe.2025.1498141","article-title":"Bridging the gap: the role of 3D cell cultures in mimicking tumor microenvironment for enhanced drug testing accuracy","volume":"13","author":"Zhou","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.7785","article-title":"Novel imine complexes incorporating ZrO (II), VO (II), and Pd (II) cations: synthesis, DFT calculation, molecular docking, antimicrobial, and antitumor activity","volume":"39","author":"Abdel-Fatah","year":"2025","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2026.109990_bb0160","doi-asserted-by":"crossref","first-page":"116131","DOI":"10.1016\/j.inoche.2025.116131","article-title":"Synthesis of Ca (II), Mg (II), and VO (II) tridentate Schiff Base complexes as potential antitumor candidates: Spectroscopic, antioxidant activity, DFT, and DNA docking studies","volume":"186","author":"Abdel-Fatah","year":"2026","journal-title":"Inorg. Chem. Commun."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109990_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/aoc.70192","article-title":"Synthesis, spectroscopic characterization, DFT studies of novel praseodymium (III), neodymium (III), and samarium (III) complexes of a tridentate Schiff base: aspects of their antimicrobial, antitumor, and biological profiles","volume":"39","author":"Abdel-Fatah","year":"2025","journal-title":"Appl. Organomet. Chem."},{"issue":"284","key":"10.1016\/j.bioorg.2026.109990_bb0170","article-title":"Advances in selective c-MET kinase inhibitors: application of fused [5, 6]-bicyclic nitrogen-containing cores for anticancer drug design","volume":"15","author":"Valipour","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0175","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/s41598-021-83069-4","article-title":"Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met","volume":"11","author":"Damghani","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109990_bb0180","doi-asserted-by":"crossref","first-page":"27302","DOI":"10.1038\/s41598-024-78468-2","article-title":"Design, synthesis, and cytotoxic activity of 2-amino-1,4-naphthoquinone-benzamide derivatives as apoptosis inducers","volume":"14","author":"Sayahi","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109990_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117367","article-title":"Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors","volume":"90","author":"Divar","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109990_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.969559","article-title":"Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors","volume":"10","author":"Mortazavi","year":"2022","journal-title":"Front. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:45:27Z","timestamp":1783158327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0045206826005262"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109990","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1,2,4-triazine moieties as potential c-MET targeting anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109990"}}